Dogwood Therapeutics stock reports a 239 patient trial milestone

Dogwood Therapeutics stock stood at USD 1.51 on Nasdaq on September 23, 2026, while its market capitalization was USD 50.78 million. The company completed enrollment of 239 patients in its Halneuron Phase 2b trial on September 14, 2026, according to Dogwood Therapeutics.

Trial enrollment reaches 239 patients

The completed recruitment covers the companys ongoing Halneuron study in chemotherapy-induced neuropathic pain. The randomized Phase 2b trial compares Halneuron with placebo and measures the change in weekly average daily pain intensity after four weeks.

The enrollment figure reached the upper end of the planned target range. Dogwood expects the topline readout in November 2026, giving the stock a defined clinical checkpoint after the September enrollment announcement.

November data create the next test

Halneuron is being developed as a non-opioid treatment for pain and neuropathy. The company describes the candidate as a selective sodium channel blocker designed to reduce pain transmission, while the trial tests whether that mechanism translates into a measurable patient benefit.

The November timetable matters because the study result is the next major value-bearing event identified by the company. A positive readout would support further development planning, while the 239-patient dataset sets a clear numerical frame for judging the outcome.

Price remains below yearly high

Dogwood Therapeutics stock was 84.1 percent below its 52-week high of USD 9.50 on September 23, 2026. The same range extended down to USD 1.28, placing the USD 1.51 quote 17.97 percent above the yearly low.

For investors, the setup combines a small biotechnology market value with a specific near-term clinical date. The share price and the November data timetable therefore provide two separate reference points for assessing how the market weighs development risk against the potential of Halneuron.